Von Hippel Lindau Blocking Peptide is synthetically produced from the 130-200 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20ยฐC for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 130-200 on human Von Hippel-Lindau disease tumor suppressor protein.
Immunogen Region
130-200
Additional Info
Tissue Specificity
Expressed in the adult and fetal brain and kidney.
Function
Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases. Ubiquitinates, in an oxygen-responsive manner, ADRB2. Acts as a negative regulator of mTORC1 by promoting ubiquitination and degradation of RPTOR.
Peptide Name
Von Hippel-Lindau Disease Tumor SuppressorProtein G7Pvhl
Isoform 1: CytoplasmCell MembranePeripheral Membrane ProteinEndoplasmic ReticulumNucleusFound Predominantly In The Cytoplasm And With Less Amounts Nuclear Or Membrane-AssociatedColocalizes With Adrb2 At The Cell MembraneIsoform 3: CytoplasmEqually Distributed Between The Nucleus And The Cytoplasm But Not Membrane-Associated
Alternative Peptide Names
Von Hippel-Lindau Disease Tumor Suppressor proteinProtein G7 proteinPvhl proteinVHL protein
